title: [Netilmicin in the treatment of bacterial respiratory tract infections].
abstract: Netilmicin - a semisynthetic aminoglycoside - was administered to 33 patients with the acute or chronic lower respiratory tract or pulmonary infections in a daily dose of 5 mg/kg body weight for 10 days. A principle criterium of patients classification to netilmicin therapy were sensitive bacterial strains either in sputum or in BAL liquid. A significant clinical improvement was noted in 88% of the treated patients. However, elimination of pathogens from the sputum was achieved only in 52% of these patients. No improvement was observed in 4% of the treated patients. No adverse reactions were noted. Netilmicin proved safe and effective antibacterial agent in patients with respiratory infections.
authors.affiliation: Kliniki Alergii i Immunologii.
authors.forename: M
authors.initials: M
authors.lastname: Wandzilak
authors.forename: P
authors.initials: P
authors.lastname: Głuszko
authors.forename: W
authors.initials: W
authors.lastname: Królikowski
authors.forename: A
authors.initials: A
authors.lastname: Prokop
authors.forename: J
authors.initials: J
authors.lastname: Soja
authors.forename: A
authors.initials: A
authors.lastname: Szczeklik
mesh_terms: D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy*; D006801:Humans; D008169:Lung Abscess / Q000188:drug therapy*; D008875:Middle Aged; D009428:Netilmicin / Q000627:therapeutic use*; D011014:Pneumonia / Q000188:drug therapy*
chemical_list: D009428:Netilmicin
vernacular_title: Netylmycyna w leczeniu bakteryjnych zakazeń układu oddechowego.